Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clover Biopharmaceuticals's ROE % for the quarter that ended in Dec. 2025 was 0.00%. Clover Biopharmaceuticals's PB Ratio for the quarter that ended in Dec. 2025 was N/A.
Clover Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.
Clover Biopharmaceuticals ROE % Adjusted to Book Value Related Terms
Clover Biopharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Clover Biopharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clover Biopharmaceuticals ROE % Adjusted to Book Value Chart
HKSE:02197 vs VRTX, REGN, RVMD: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Clover Biopharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Biopharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Clover Biopharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Clover Biopharmaceuticals (HKSE:02197) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Clover Biopharmaceuticals and its competitors.
Is Clover Biopharmaceuticals' ROE % Adjusted to Book Value too high?
Clover Biopharmaceuticals' current ROE % Adjusted to Book Value is 0.00%. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' ROE % Adjusted to Book Value compare to VRTX and REGN?
Clover Biopharmaceuticals' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Clover Biopharmaceuticals and its competitors. Clover Biopharmaceuticals's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score
Get the complete analysis for HKSE:02197
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02197 has been successfully added to your 
